Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
about
Aldosterone antagonists for preventing the progression of chronic kidney diseaseAldosterone antagonists for preventing the progression of chronic kidney diseaseRecent advances in managing and understanding diabetic nephropathyPharmacologic management of chronic reno-cardiac syndromeMineralocorticoid receptor blockade in chronic kidney diseaseAntihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone systemCharacterization of structure and function of ZS-9, a K+ selective ion trapLong-term effects of spironolactone in peritoneal dialysis patientsSpironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.Aldosterone receptor antagonists: effective but often forgotten.A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patientsThe effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysisHyperkalemia of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in hemodialysis: a meta-analysis.Hypertension in chronic kidney disease: navigating the evidence.Changes in the perceived epidemiology of primary hyperaldosteronismHypertension in Cardiovascular and Kidney Disease.Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney diseaseAldosterone-to-renin ratio acts as the predictor distinguishing the primary aldosteronism from chronic kidney disease.Antioxidants in kidney diseases: the impact of bardoxolone methyl.Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisComorbid Heart Failure and Renal Impairment: Epidemiology and Management.Analysis of baseline parameters in the HALT polycystic kidney disease trials.Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentreRenoprotective effect of combined inhibition of angiotensin-converting enzyme and histone deacetylase.Maintenance of serum potassium with sodium zirconium cyclosilicate (ZS-9) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial.Proteinuria and its relation to cardiovascular disease.New therapeutic agents in diabetic nephropathy.I brazilian position paper on antihypertensive drug combinationSpironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Application of direct renin inhibition to chronic kidney disease.ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations.Pathogenesis and therapeutic implications of cardiorenal syndrome.Mineralocorticoid receptor blockade in chronic kidney disease.Managing kidney disease with blood-pressure control.Evolution of treatment for diabetic nephropathy: historical progression from RAAS inhibition and onward.An update on the pathomechanisms and future therapies of Alport syndrome.Improving the efficacy of RAAS blockade in patients with chronic kidney disease.Role of Rac1-mineralocorticoid-receptor signalling in renal and cardiac disease.Management of cardiovascular disease in patients with kidney disease.Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.
P2860
Q24194979-C738718C-54E3-48E0-A09A-B9534554F420Q24239909-7D2D981E-0953-4CFE-AF8C-E8641CC36816Q26745900-470209F2-B32A-484C-911D-1AB361F27670Q26829812-4802009E-1DBA-47D2-B1CF-E8CC8A978A0BQ26864370-6B2E9813-DF60-4532-9B0C-2F875D92ED07Q26865691-BED72DBB-3AC4-47B9-8366-0735E6EE27C5Q28542799-3CB8B39E-7D9A-4190-90B9-5F33EBEEBA81Q30413119-F954263C-EDBC-47A0-8656-1C3FD6DED93AQ30585060-E17A8298-C3F7-4B58-8D9F-D6342223502CQ33688485-1F86F81C-A0A2-408F-BE51-443B777C9935Q34075463-E6C9EE14-3D6C-4870-A3CA-23B249050600Q34122611-D9608BB3-22C6-4A3D-98F4-83F6E7A3B44FQ34449065-E4EBCEAD-F3BC-40B0-A7EB-AB522B81D00EQ35071147-6CE007A4-8E07-440E-BC8F-BC20B3FAF14EQ35151575-BE2FFBD9-793E-48DA-B643-75B23DFF5076Q35203404-53E7249E-7154-46CA-BD5A-A2DD847CD2D9Q35626544-65460192-3D4C-43F3-A6C3-928CD53BFBE1Q35919186-992369A6-2A4E-41B8-BED8-D16D19C723B9Q36026304-F136E4D6-CAF2-4099-B5FA-84DA4DE131FAQ36127484-52D62AEF-6357-4048-8F28-8025D190E917Q36551356-7A4C219C-A115-485C-838B-6D34BA332F39Q36634612-58EED4B4-01A9-4422-9B61-9B2566C09893Q36670632-A4C4A4C1-0E87-4231-A366-0D16AE056B18Q36796579-D6F3160F-C666-494C-9242-DC24A8AA3EBBQ37275785-E852285D-763F-4ABE-9359-7F0B7A7B4007Q37414937-216AE63D-2AF1-49A9-B64E-6583811B9CCDQ37559164-D81883A6-3DA6-4303-9412-DF91031A0387Q37703801-1BD32787-FBE3-4B22-ADAA-0AFCBBE6C9B5Q37709432-763330C9-18F6-4972-9748-581D123BB103Q37758534-74866195-4D6A-462F-BFAA-9EE1FE37D564Q37803232-8CA30551-417B-4062-8331-EE24D42C39D7Q37812022-2F732F8F-D5DC-47AA-AEB3-38793F12E2F0Q37861583-9AE179B5-2F74-4B37-9936-9F2FC5563046Q37892340-F77787D7-21AB-4165-B18C-BE157C2CC89FQ37959165-DE9C77A1-AA89-4D71-9750-8A05151ED26AQ38035773-EE1CBB06-F914-41BA-8A20-7B79736637DBQ38068099-B7A2459D-CF00-4074-B121-0ABA1B274491Q38072297-637EE0F6-76BA-4FBB-B9FC-B9C45E0CA3CFQ38082646-003362CC-5C45-448C-A866-42DE77F8959BQ38087529-5A40332C-58F2-4F8B-A13E-24A80902CFCF
P2860
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@ast
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@en
type
label
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@ast
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@en
prefLabel
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@ast
Aldosterone antagonists for pr ...... atic review and meta-analysis.
@en
P2093
P2860
P356
P1476
Aldosterone antagonists for pr ...... matic review and meta-analysis
@en
P2093
Ashwini R Sehgal
Sagar U Nigwekar
Sankar D Navaneethan
P2860
P304
P356
10.2215/CJN.04750908
P577
2009-03-04T00:00:00Z